Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has downgraded Editas Medicine Inc (EDIT) to Neutral from Overweight due to competition in sickle cell therapy. Editas' EDIT-301 is running two years behind Vertex Pharmaceuticals/CRISPR Therapeutics AG's (CRSP) exa-cel and Bluebird Bio Inc's (BLUE) lovo-cel. The development of EDIT-301 is expected to be associated with limited value creation. EDIT shares are down 4.68% at $6.92.
October 17, 2023 | 6:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Editas Medicine Inc has been downgraded by Cantor Fitzgerald due to competition in sickle cell therapy. Its EDIT-301 is running two years behind competitors' therapies.
The downgrade by Cantor Fitzgerald is due to the competition in sickle cell therapy. Editas' EDIT-301 is running two years behind its competitors' therapies, which could limit its market share and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bluebird Bio Inc's lovo-cel is ahead of Editas Medicine Inc's EDIT-301 in the development of sickle cell therapy.
Bluebird Bio Inc's lovo-cel is ahead in the development of sickle cell therapy, which could potentially lead to a larger market share and increased profitability.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Vertex Pharmaceuticals/CRISPR Therapeutics AG's exa-cel is ahead of Editas Medicine Inc's EDIT-301 in the development of sickle cell therapy.
CRISPR Therapeutics AG's exa-cel is ahead in the development of sickle cell therapy, which could potentially lead to a larger market share and increased profitability.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 60